WO2005085288A2 - Natural igm antibodies and inhibitors thereof - Google Patents

Natural igm antibodies and inhibitors thereof Download PDF

Info

Publication number
WO2005085288A2
WO2005085288A2 PCT/US2005/006276 US2005006276W WO2005085288A2 WO 2005085288 A2 WO2005085288 A2 WO 2005085288A2 US 2005006276 W US2005006276 W US 2005006276W WO 2005085288 A2 WO2005085288 A2 WO 2005085288A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
nucleic acid
antibody
igm
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/006276
Other languages
English (en)
French (fr)
Other versions
WO2005085288A3 (en
Inventor
Michael C. Carroll
Jr. Francis D. Moore
Herbert B. Hechtman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
CBR Institute for Biomedical Research Inc
Harvard University
Original Assignee
Brigham and Womens Hospital Inc
CBR Institute for Biomedical Research Inc
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT05723931T priority Critical patent/ATE498010T1/de
Priority to JP2007501869A priority patent/JP5557982B2/ja
Priority to DE602005026260T priority patent/DE602005026260D1/de
Priority to EP05723931A priority patent/EP1725659B1/en
Priority to CN200580012909.8A priority patent/CN1977043B/zh
Priority to AU2005219839A priority patent/AU2005219839B9/en
Application filed by Brigham and Womens Hospital Inc, CBR Institute for Biomedical Research Inc, Harvard University filed Critical Brigham and Womens Hospital Inc
Priority to CA002560066A priority patent/CA2560066A1/en
Publication of WO2005085288A2 publication Critical patent/WO2005085288A2/en
Publication of WO2005085288A3 publication Critical patent/WO2005085288A3/en
Priority to IL177825A priority patent/IL177825A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Definitions

  • Figure 7C is a series of photomicrographs showing the absence of IgM and complement C3 or C4 within the microvilli of P8-treated animals.
  • Representative cryosections of intestinal tissues were harvested following intestinal RL
  • Panels i-viii are IgM CM"22 reconstituted RAG-l " mice without pretreatment with P S (panels i-iv) or with P8 (panels v-viii).
  • Panels represent cryosections from the intestines of WT without P8 (panels ix - xii) or pretreated with P8 (panels xiii - xvi).
  • Figure 14 shows the (A) nucleic acid sequence (SEQ ID NO: 53; Genbank Accession no. NM_005964) and (B) amino acid sequence (SEQ ID NO: 54; Genbank Accession no. NP_005955) of human non-muscle myosin heavy chain II-B (hNMHC-IIB).
  • Figure 15 shows the (A) nucleic acid sequence (SEQ ID NO: 55; Genbank
  • the coding sequences need not be contiguous to one another so long as the expressed sequences ultimately process to produce the desired protein.
  • An expression control sequence operatively linked to a coding sequence is ligated such that expression of the coding sequence is achieved under conditions compatible with the expression control sequences.
  • expression control sequences refers to nucleic acid sequences that regulate the expression of a nucleic acid sequence to which it is operatively linked. Expression control sequences are operatively linked to a nucleic acid sequence when the expression control sequences control and regulate the transcription and, as appropriate, translation of the nucleic acid sequence.
  • an isolated nucleic acid can comprise an IgM CM"22 (or 22A5 IgM) heavy chain variable region nucleotide sequence having a nucleotide sequence as shown in Figure 1 A (SEQ ID NO: 1), or a sequence, which is at least 80%, 90%, 95%, 96%, 97%, 98%o, or 99% identical to SEQ ID NO: 1.
  • a nucleic acid molecule may comprise the heavy chain CDR1 nucleotide sequence of SEQ ID NO: 3, or a portion thereof. Further, the nucleic acid molecule may comprise the heavy chain CDR2 nucleotide sequence of SEQ ID NO: 5, or a portion thereof.
  • the nucleic acid molecule comprises a light chain CDRl nucleotide sequence of SEQ ID NO: 9, or portion thereof, and a light chain CDR2 nucleotide sequence of SEQ ID NO: 11 , or portion thereof.
  • the nucleic acid molecules of the present invention may comprise light chain sequences, e.g. SEQ ID NOs: 7, 9 or 11, or combinations thereof, or encompass nucleotides having at least 80%, 90%, 95%, 96%, 97 %, 98%, and 99% sequence identity to SEQ ID NOs: 7, 9 or 11.
  • Further nucleic acid molecules may comprise light chain sequences, which hybridize under stringent conditions, e.g.
  • Chimeric antibodies e.g. mouse-human monoclonal antibodies
  • Chimeric antibodies can be produced by recombinant DNA techniques known in the art. For example, a gene encoding the Fc constant region of a murine (or other species) monoclonal antibody molecule is digested with restriction enzymes to remove the region encoding the murine Fc, and the equivalent portion of a gene encoding a human Fc constant region is substituted, (see Robinson et al., International Patent Publication PCT/US86/02269; Akira, et al., European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Mo ⁇ ison et al., European Patent Application 173,494; Neuberger et al., International Application WO 86/01533; Cabilly et al.
  • the method includes: altering the sequence, e.g., by substitution or deletion of one or more residues, of a pathogenic immunoglobulin, e.g., altering the sequence of a non-conserved region, or a domain or residue described herein, and testing the altered polypeptide for the desired activity.
  • the modified natural immunoglobulin may have a reduced ability to activate complement. For example, one or more of the amino acid residues involved in complement binding and/or activation are mutated.
  • a change e.g., decrease in the level of binding between the natural IgM antibody and the antigen or the component of the complement pathway in the presence of the test compound relative to that detected in the absence of the test compound indicates that the test compound is an inhibitor of the interaction between the natural IgM antibody and the antigen or the component of the complement pathway.
  • the method can further include pre-treating the natural IgM antibodies with one or more test compounds.
  • the pre-treated natural IgM antibodies can then be injected into mice deficient in natural immunoglobulins.
  • the methods is perfo ⁇ ried in vitro.
  • the contacting step is effected in vivo.
  • the antigen is myosin.
  • the aliquots of derivatized beads are then washed, "pooled” (i.e., recombined), and the pool of beads is again divided, with each aliquot being placed in a separate reaction vessel.
  • Another activated amino acid is then added to each aliquot of beads. The cycle of synthesis is repeated until a desired peptide length is obtained.
  • Activated cells are hybridized with fusion partner myeloma cells in the presence of PEG and grown in HAT-selective medium.
  • Hybridomas are screened for IgM secreting clones by ELISA , and positive wells are expanded for purification of IgM.
  • Twenty-two IgM-secreting hybridoma clones were analyzed by pooling an equal amount of IgM product from each of the clones.
  • Treatment of antibody-deficient mice with the pooled IgM restored injury similar to that seen with pooled IgM from serum. This finding confirmed that the pathogenic IgM was among the twenty-two hybridomas produced.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/US2005/006276 2004-03-01 2005-03-01 Natural igm antibodies and inhibitors thereof Ceased WO2005085288A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2007501869A JP5557982B2 (ja) 2004-03-01 2005-03-01 天然ＩｇＭ抗体およびその阻害剤
DE602005026260T DE602005026260D1 (de) 2004-03-01 2005-03-01 Natürliche igm-antikörper und inhibitoren davon
EP05723931A EP1725659B1 (en) 2004-03-01 2005-03-01 Natural igm antibodies and inhibitors thereof
CN200580012909.8A CN1977043B (zh) 2004-03-01 2005-03-01 天然IgM抗体及其抑制剂
AU2005219839A AU2005219839B9 (en) 2004-03-01 2005-03-01 Natural IgM antibodies and inhibitors thereof
AT05723931T ATE498010T1 (de) 2004-03-01 2005-03-01 Natürliche igm-antikörper und inhibitoren davon
CA002560066A CA2560066A1 (en) 2004-03-01 2005-03-01 Natural igm antibodies and inhibitors thereof
IL177825A IL177825A (en) 2004-03-01 2006-08-31 PEPTIDE INHIBITOR OF AN IgM MOLECULE, NUCLEIC ACID ENCODING THE SAME, VECTOR COMPRISING THE NUCLEIC ACID, HOST CELL COMPRISING THE VECTOR, COMPOSITION COMPRISING THE INHIBITOR AND USE OF THE COMPOSITION

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54912304P 2004-03-01 2004-03-01
US60/549,123 2004-03-01
US58864804P 2004-07-16 2004-07-16
US60/588,648 2004-07-16

Publications (2)

Publication Number Publication Date
WO2005085288A2 true WO2005085288A2 (en) 2005-09-15
WO2005085288A3 WO2005085288A3 (en) 2006-08-03

Family

ID=34922704

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/006276 Ceased WO2005085288A2 (en) 2004-03-01 2005-03-01 Natural igm antibodies and inhibitors thereof

Country Status (9)

Country Link
US (5) US7442783B2 (OSRAM)
EP (2) EP2290077B1 (OSRAM)
JP (3) JP5557982B2 (OSRAM)
AT (1) ATE498010T1 (OSRAM)
AU (1) AU2005219839B9 (OSRAM)
CA (1) CA2560066A1 (OSRAM)
DE (1) DE602005026260D1 (OSRAM)
IL (1) IL177825A (OSRAM)
WO (1) WO2005085288A2 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324352B2 (en) 2009-12-07 2012-12-04 Decimmune Therapeutics, Inc. Anti-inflammatory antibodies and uses therefor
US9243059B2 (en) 2013-03-12 2016-01-26 Decimmune Therapeutics, Inc. Humanized anti-N2 antibodies and methods of treating ischemia-reperfusion injury

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2560066A1 (en) * 2004-03-01 2005-09-15 The Cbr Institute For Biomedical Research, Inc. Natural igm antibodies and inhibitors thereof
US20100136684A1 (en) * 2004-03-01 2010-06-03 Carroll Michael C Natural IgM Antibodies
CN103221062A (zh) * 2010-06-03 2013-07-24 阿布拉西斯生物科学有限责任公司 外周血sparc 结合抗体及其用途
WO2014055392A2 (en) * 2012-10-01 2014-04-10 Decimmune Therapeutics, Inc. Method of protecting cardiac function
JP6551825B2 (ja) * 2014-02-10 2019-07-31 公立大学法人首都大学東京 クロマチン構造制御剤

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5266480A (en) 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990002909A1 (en) 1988-09-06 1990-03-22 Asarco Incorporated Method and burner for melting copper
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
WO1991007087A1 (en) 1989-11-13 1991-05-30 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
WO1991008756A1 (en) * 1989-12-12 1991-06-27 Biomedical Research Institute Novel malarial sporozoite peptide antigens
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
ES2155822T3 (es) 1990-12-06 2001-06-01 Affymetrix Inc Compuestos y su utilizacion en una estrategia de sintesis binaria.
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5677195A (en) 1991-11-22 1997-10-14 Affymax Technologies N.V. Combinatorial strategies for polymer synthesis
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5359115A (en) 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
EP0665897B1 (en) 1992-10-01 2003-07-09 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5362899A (en) 1993-09-09 1994-11-08 Affymax Technologies, N.V. Chiral synthesis of alpha-aminophosponic acids
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6376653B1 (en) 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
CA2353563A1 (en) * 1998-12-03 2000-06-08 Targanta Therapeutics Inc. Development of novel anti-microbial agents based on bacteriophage genomics
WO2001064835A2 (en) * 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001088088A2 (en) * 2000-05-18 2001-11-22 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2000042210A2 (en) * 1999-01-15 2000-07-20 International Paper Company Microsatellite dna markers and uses thereof
US6753314B1 (en) * 1999-04-01 2004-06-22 Curagen Corporation Protein-protein complexes and methods of using same
US6355481B1 (en) * 1999-06-18 2002-03-12 Emory University Hybridoma cell line and monoclonal antibody for huntingtin protein
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
CA2410458A1 (en) * 2000-06-08 2001-12-13 The Center For Blood Research, Inc. Methods and compositions for inhibiting immunoglobulin-mediated__reperfusion injury
EP2113516B1 (en) * 2000-10-10 2014-05-21 Genentech, Inc. Antibodies against C5 inhibiting type II endothelial cell activation
WO2002096948A2 (en) * 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20040131607A1 (en) 2001-06-08 2004-07-08 Carroll Michael C. Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury
AU2002357382A1 (en) * 2001-12-21 2003-07-30 Diadexus, Inc. Compositions and methods relating to endometrial specific genes and proteins
WO2003055982A2 (en) * 2001-12-21 2003-07-10 Diadexus, Inc. Compositions and methods relating to endometrial specific genes and proteins
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
CA2560066A1 (en) 2004-03-01 2005-09-15 The Cbr Institute For Biomedical Research, Inc. Natural igm antibodies and inhibitors thereof
US20100136684A1 (en) 2004-03-01 2010-06-03 Carroll Michael C Natural IgM Antibodies
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324352B2 (en) 2009-12-07 2012-12-04 Decimmune Therapeutics, Inc. Anti-inflammatory antibodies and uses therefor
EP2510000A4 (en) * 2009-12-07 2013-07-24 Decimmune Therapeutics Inc Anti-inflammatory antibodies and applications thereof
US9243059B2 (en) 2013-03-12 2016-01-26 Decimmune Therapeutics, Inc. Humanized anti-N2 antibodies and methods of treating ischemia-reperfusion injury
US9409977B2 (en) 2013-03-12 2016-08-09 Decimmune Therapeutics, Inc. Humanized, anti-N2 antibodies

Also Published As

Publication number Publication date
IL177825A (en) 2013-02-28
JP2014155497A (ja) 2014-08-28
EP1725659B1 (en) 2011-02-09
EP1725659A2 (en) 2006-11-29
AU2005219839B9 (en) 2011-12-22
DE602005026260D1 (de) 2011-03-24
AU2005219839B2 (en) 2011-11-24
EP2290077B1 (en) 2016-01-27
EP2290077A3 (en) 2011-05-18
WO2005085288A3 (en) 2006-08-03
JP2011139704A (ja) 2011-07-21
EP2290077A2 (en) 2011-03-02
US20090176966A1 (en) 2009-07-09
US7442783B2 (en) 2008-10-28
JP5557982B2 (ja) 2014-07-23
IL177825A0 (en) 2006-12-31
CA2560066A1 (en) 2005-09-15
HK1154904A1 (en) 2012-05-04
JP5618852B2 (ja) 2014-11-05
US9657060B2 (en) 2017-05-23
US20140127214A1 (en) 2014-05-08
JP2008504807A (ja) 2008-02-21
AU2005219839A1 (en) 2005-09-15
US20170342109A1 (en) 2017-11-30
US9914751B2 (en) 2018-03-13
US20160280740A1 (en) 2016-09-29
US20050276811A1 (en) 2005-12-15
ATE498010T1 (de) 2011-02-15

Similar Documents

Publication Publication Date Title
US9914751B2 (en) Natural IGM antibodies and inhibitors thereof
US7875259B2 (en) Biological materials and methods useful in the diagnosis and treatment of diseases
KR20230082071A (ko) SARS-CoV-2 변이체들에 특이적으로 결합하는 항체
US20100136684A1 (en) Natural IgM Antibodies
US20040131607A1 (en) Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury
AU2012200909B2 (en) Natural lgM antibodies and inhibitors thereof
CN1977043B (zh) 天然IgM抗体及其抑制剂
HK1154904B (en) Natural igm antibodies and inhibitors thereof
EP1286682B1 (en) Methods and compositions for inhibiting immunoglobulin-mediated-reperfusion injury
HK1150533A (en) Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury
HK1195260A1 (zh) Fc受体结合蛋白

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2560066

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007501869

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005219839

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005723931

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005219839

Country of ref document: AU

Date of ref document: 20050301

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005219839

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580012909.8

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005723931

Country of ref document: EP